About 25 % of bladder cancer presents initially as muscle invasive
Majority of muscle invasive patients present de novo – about 20 % of muscle invasive bladder cancers are patients who have progressed from NMIBC
25 – 50 % will have micrometastatic disease (nodal or distant) at the time of cystectomy.
85 % will die within 2 years if left untreated.
Death after local treatment is usually due to distant or systemic disease – with majority of deaths occurring within 2 years.
Both nodal and haematogenous spread – pelvic nodal disease most common, but a third of metastatic cases (liver, lung, bone, adrenal) will not have obvious nodal disease first.
Staging
Clinical staging – bimanual EUA pre and post TURBT
Pathological staging – on TURBT or cystectomy
Radiological staging:
- CT chest / abdo / pelvis is routine for metastatic and nodal staging
- Widely available
- Nodal sensitivity is limited (high false negatives)
- Local T staging is limited – can’t differentiate muscle layers and may be compromised by artefact post-op
- Allows assessment of upper tracts and hydronephrosis
- MRI
- Probably better local staging with more accurate differentiation between T1 and T2 and T3
- Useful for T4 disease and questions of organ invasion and resectability
- Equivalent for nodal assessment (i.e., still understages nodes)
- VIRADs score can be given based on multiparametric appearances
- Need experienced radiologist and centre
- MRI abdomen can be used as alternative for follow up surveillance if CT contraindicated
- Bone scan
- Not routine – consider if raised ALP or other concerns on CT needing clarification
- FDG PET
- Local staging limited by radiourine
- Not as accessible or available as usual CT
- Emerging evidence FDG PET may be more sensitive than CT for nodal and metastatic disease – often useful for equivocal nodes
Management options for muscle invasive bladder cancer
- Radical cystectomy and PLND
- +/- neoadjuvant chemotherapy
- Trimodal therapy
- Maximal TURBT, chemotherapy and radiotherapy
- Partial cystectomy
- Radiation therapy alone (+ TURBT)
- Best endoscopic management
Recommend multidisciplinary approach and inform patients of all options.